Medikit Co.,Ltd.

Medikit Co.,Ltd.

7749.T
Medikit Co.,Ltd.JP flagTokyo Stock Exchange
2,810.00
JPY
+14.00
- -
40.68BMarket Cap
Medikit Co.,Ltd.
7749.T
(Tokyo Stock Exchange)

Recent

price

2,810.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
736.87
754.89
747.61
776.39
811.13
927.34
993.9
1,028.97
1,091.23
1,173.29
1,142.96
1,198.18
1,287.37
1,337.96
1,530.84
1,632.62
743.68
Revenue per Share
112.88
108.62
97.81
104.01
119.31
136.1
135.41
145.4
151.95
170.33
157.37
178.15
170.67
187.95
204.55
206.37
118.19
Basic EPS, GAAP
118.91
60.97
96.72
102.69
84.02
148.6
81.38
120.75
120.18
123.34
123.89
81.48
205.83
191.54
-19.55
85.94
- -
Free Cash Flow per Basic Share
25.02
24.96
27.49
27.49
29.13
32.47
34.99
37.5
37.5
44.99
50.16
49.68
89.94
107.26
90.19
96.66
- -
Dividend per Share
1,026.31
1,109.16
1,176.21
1,252.72
1,370.38
1,583.43
1,683.84
1,791.74
1,906.09
2,031.42
2,145.58
2,285.98
2,368.98
2,514.65
2,618.84
2,759.7
2,802.43
Book Value per Share
1,564.4
1,650.2
1,721.17
1,805.11
1,799.24
2,028.94
2,106.67
2,213.16
2,330.92
2,464.26
2,567.94
2,716.84
2,633.44
2,489.25
2,842.21
3,008.79
2,789.78
Tangible Book Value per Share
19
19
19
19
18
17
17
17
17
17
17
17
17
16
15
15
15
Basic Weighted Avg Shares
13,779
14,127
13,991
14,529
14,850
15,722
16,851
17,445
18,502
19,893
19,313
20,131
21,607
21,851
22,553
23,781
11,005
Sales/Revenue/Turnover
25.75
25.96
21.79
21.64
23.14
22.92
20.84
20.84
20.91
21.76
19.57
21.97
19.06
21.41
19.89
17.97
21.82
Operating Margin (%)
648
629
769
720
924
883
921
1,014
1,178
1,319
1,309
1,270
1,324
1,545
1,690
2,039
- -
Depreciation Expense
2,111
2,033
1,830
1,946
2,184
2,308
2,296
2,465
2,576
2,888
2,659
2,993
2,865
3,069
3,014
3,006
1,749
Net Income, GAAP
41.27
44.03
39.16
39.84
37.52
36.99
34.91
33.69
33.82
33.38
32.32
33.08
33.25
35.72
35.33
33.38
26.43
Effective Tax Rate (%)
15.32
14.39
13.08
13.4
14.71
14.68
13.62
14.13
13.92
14.52
13.77
14.87
13.26
14.05
13.36
12.64
15.89
Profit Margin (%)
22,249
23,115
24,685
25,483
24,859
26,694
28,012
29,108
30,627
32,441
33,470
34,127
33,503
28,772
27,084
27,901
27,774
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
14
- -
LT Debt
29,320
30,900
32,241
33,805
32,964
34,491
36,357
38,148
40,049
42,169
43,637
45,772
47,292
44,129
45,156
46,781
44,655
Total Equity
7.11
6.65
5.77
5.63
6.32
6.61
6.32
6.36
6.45
6.9
5.88
6.54
5.82
6.46
6.37
6.08
3.75
Return on Invested Capital (%)
11.52
10.2
8.59
8.58
9.02
8.9
8.3
8.38
8.23
8.67
7.54
8.03
7.34
7.61
7.58
7.64
4.31
Return on Capital (%)
11.49
10.18
8.56
8.56
9
8.89
8.29
8.37
8.22
8.65
7.52
8.02
7.33
7.6
7.57
7.63
4.3
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
- -
15
Market Capitalization
50,358
43,639
42,795

Working Capital

FRC

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
34,491
- -
34,021
Cash, Cash Equivalents & STI
23,611
- -
22,843
Accounts Receivable, Net
5,289
- -
5,127
Inventories
3,877
- -
4,191
Total Current Liabilities
5,719
- -
6,248
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.15%
1.49%
3.6%
Free Cash Flow
-53.01%
-107.1%
-534.59%
Net Income, GAAP
2.89%
2.67%
-0.25%
Sales/Revenue/Turnover
4.27%
4.27%
5.45%
Total Cash Common Dividend
12.32%
15.44%
5.97%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,550
5,296
6,015
4,990
21,851
2025
- -
- -
- -
- -
22,553
2026
- -
- -
- -
- -
23,781

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33.62
- -
- -
- -
187.95
2025
- -
- -
- -
- -
204.55
2026
- -
- -
- -
- -
206.37

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
107.26
2025
- -
- -
- -
- -
90.19
2026
- -
- -
- -
- -
96.66
Business
Medikit Co., Ltd. manufactures and sells vascular access medical devices primarily for dialysis, infusion, and interventional cardiology procedures. The company offers a comprehensive range of products including IV catheters such as Supercath 5 and Supercath Z3V; hemodialysis catheters and indwelling needles for artificial dialysis; inner needles; blood control caps; angiography equipment comprising sheath introducers, Super Sheath, and angiographic catheters; and other devices used in anesthetic departments, operating theaters, ICUs, dialysis units, and cardiology units worldwide. Medikit operates mainly in Japan with sales in the United States and over 30 other countries through subsidiaries including Togo Medikit Co., Ltd., Medikit Vietnam Co., Ltd., and Medikit Europe GmbH. Founded on June 15, 1973, the company is headquartered at 1-13-2 Yushima, Bunkyo-ku, Tokyo, Japan. In December 2024, Medikit entered a new distribution partnership with Inari Medical for the ClotTriever thrombectomy system in Japan, enhancing its interventional product portfolio with reimbursement approval.